Cuál es el precio por Ergomed plc (2EM)

Precio por Ergomed plc (2EM) es de$13.05

Cuál es la capitalización de mercado por Ergomed plc (2EM)

Capitalización de mercado por Ergomed plc (2EM) es $695.07M

Ergomed plc (2EM) EPS

Ergomed plc, alongside its affiliated entities, offers a comprehensive range of clinical trial services, encompassing planning, oversight, and execution, in addition to providing essential drug safety and medical information support. The company maintains an expansive global footprint, conducting operations throughout the United Kingdom, continental Europe, the Middle East, Africa, North America, Asia, and Australia. Its business is organized into two core divisions: Clinical Research Services and Pharmacovigilance. Ergomed assists pharmaceutical, biotechnology, and generic drug manufacturers by managing clinical development programs, facilitating post-market approval strategies, and delivering robust pharmacovigilance solutions. Their expertise is concentrated in several therapeutic domains, including oncology, haematology, allergy, respiratory, and neurology/CNS, with a notable specialization in the development of orphan drugs. Furthermore, they extend support services to clinical trial sites. Established in 1997, the organization originally traded as Ergomed Clinical Research Limited before rebranding as Ergomed plc in June 2014. Its corporate headquarters are situated in Guildford, United Kingdom.

Año	EPS	Cambiar
Not enough data for the provided dates.

Año

EPS

Cambiar

Not enough data for the provided dates.

Empresa	EPS	Diferencia de EPS	País
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
CSL Limited CSL.AX	$-5.29	-	AU
Moderna, Inc. MRNA.US	$-7.98	-	US
Lonza Group AG LONN.SW	-	-	CH

Empresa

EPS

Diferencia de EPS

País

Vertex Pharmaceuticals Incorporated

VRTX.US

$17.32

Argenx SE

ARGX.US

$27.74

CSL Limited

CSL.AX

$-5.29

Moderna, Inc.

MRNA.US

$-7.98

Lonza Group AG

LONN.SW

Ergomed plc

2EM

Categoría